文献速递泌尿生殖技术与安全MRUS

影像引导前列腺穿刺活检技术的成本效果比较:系统经直肠超声、直接MRI引导与影像融合

Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion.
PubMed 文献 · AJR Am J Roentgenol · 2017-02-22

本研究采用决策树和马尔可夫模型比较系统经直肠超声、直接MRI引导和影像融合引导三种前列腺穿刺策略的成本效果。融合引导活检相比系统经直肠超声活检的增量成本效果比为每获得一个质量调整生命年1386欧元(1470美元),低于80000欧元意愿支付阈值,假定具有成本效果。直接MRI引导活检的敏感度需至少达88.8%才具成本效果。

要点

  • 融合引导活检相比系统经直肠超声活检的增量成本效果比为每质量调整生命年1386欧元,低于80000欧元阈值。
  • 若临床显著前列腺癌患者MRI表现正常,直接MRI引导活检敏感度需至少达88.8%才具成本效果。
  • 缺乏直接MRI引导活检准确性的合适文献,故采用阈值分析。

核心结论

  • 融合引导活检相比系统经直肠超声引导活检似乎具有成本效果;未来研究需确定直接MRI引导活检是否为最佳路径,本研究计算了其具有成本效果的阈值。

研究设计与样本

  • 决策树和马尔可夫模型,输入来自文献综述和专家意见;以每获得一个质量调整生命年的增量成本效果比不超过80000欧元(约合2017年1月85000美元)意愿支付阈值判定成本效果;基础病例分析比较系统经直肠超声和影像融合引导活检;因缺乏直接MRI引导活检准确性的合适文献,进行阈值分析。

诊断标准与关键数值

  • 融合引导活检相比系统经直肠超声引导活检的增量成本效果比为每质量调整生命年1386欧元(1470美元),低于80000欧元意愿支付阈值,假定具有成本效果。
  • 若临床显著前列腺癌患者MRI表现正常,直接MRI引导活检的敏感度需至少达88.8%,此时增量成本效果比为每质量调整生命年80000欧元,具有成本效果。

局限性

  • 缺乏关于直接MRI引导活检准确性的合适文献,故进行阈值分析。
  • 未来研究需确定直接MRI引导活检是否为最佳路径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Three commonly used prostate biopsy approaches are systematic transrectal ultrasound guided, direct in-bore MRI guided, and image fusion guided. The aim of this study was to calculate which strategy is most cost-effective.

MATERIALS AND METHODS: A decision tree and Markov model were developed to compare cost-effectiveness. Literature review and expert opinion were used as input. A strategy was deemed cost-effective if the costs of gaining one quality-adjusted life year (incremental cost-effectiveness ratio) did not exceed the willingness-to-pay threshold of €80,000 (≈$85,000 in January 2017). A base case analysis was performed to compare systematic transrectal ultrasound- and image fusion-guided biopsies. Because of a lack of appropriate literature regarding the accuracy of direct in-bore MRI-guided biopsy, a threshold analysis was performed.

RESULTS: The incremental cost-effectiveness ratio for fusion-guided biopsy compared with systematic transrectal ultrasound-guided biopsy was €1386 ($1470) per quality-adjusted life year gained, which was below the willingness-to-pay threshold and thus assumed cost-effective. If MRI findings are normal in a patient with clinically significant prostate cancer, the sensitivity of direct in-bore MRI-guided biopsy has to be at least 88.8%. If that is the case, the incremental cost-effectiveness ratio is €80,000 per quality-adjusted life year gained and thus cost-effective.

CONCLUSION: Fusion-guided biopsy seems to be cost-effective compared with systematic transrectal ultrasound-guided biopsy. Future research is needed to determine whether direct in-bore MRI-guided biopsy is the best pathway; in this study a threshold was calculated at which it would be cost-effective.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Venderink W, Govers TM, de Rooij M, et al. Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion. AJR Am J Roentgenol. 2017. PMID: 28225639. doi:10.2214/AJR.16.17322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。